Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Alkermes, the most common co-covered peer. They are better corroborated than the beat average, carrying 20 original sources each against 4.7 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ExlService
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Alkermes, the most common co-covered peer. They are better corroborated than the beat average, carrying 20 original sources each against 4.7 for the same window. The 7 average consequence score is above the beat benchmark of 5.6 in the same window. We currently track 1 Healthcare story that mention ExlService, all published on February 26, 2026.
Stories tracked
1
Sources per story
20
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ExlService. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle for healthcare and health IT firms reveals a sector-wide shift toward AI-driven diagnostics and high-margin orphan drug commercialization. While medical device firms face cyclical equipment sales challenges, specialized biotech and diagnostic players like Veracyte and Soleno are reporting record profitability and rapid market penetration.
ExlService is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.